Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aracytidine 5'-monophosphate (ara-CMP) is a pyrimidine ribonucleoside monophosphate and the phosphorylated metabolite of cytarabine (aracytidine/ara-C). It consists of a phosphate group attached to the nucleoside aracytidine (cytosine arabinoside), which features an arabinose sugar instead of ribose. As a nucleotide analog, it is primarily used in research settings and not as an approved pharmaceutical agent. In cells, ara-CMP can be further phosphorylated to its active triphosphate form (ara-CTP), which incorporates into DNA during replication and inhibits DNA polymerase activity—leading to inhibition of DNA synthesis and cell death. This mechanism underlies the antileukemic effects observed with its parent compound cytarabine[1][3]. Aracytidine 5’-monophosphate itself is not marketed as a drug but serves as an important intermediate in understanding nucleoside analog metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aracytidine 5'-monophosphate.